Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-os-mal-iii
AssigneeUniwersytet Lodzki
InventorsIDA FRANIAK-PIETRYGA, MARIA BRYSZEWSKA, DEITMAR APPELHANS, BARBARA KLAJNERT-MACULEWICZ
Life of this patent
Estimating the term…
Abstract
The application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III containing 25-45% of peripheral amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia.
Claims9
(canceled)
(canceled)
A maltotriose-coated 4th generation polypropyleneimine dendrimer—PPI-G4-OS-Mal-III of Pattern 1, wherein R stands for a maltotriose residue, for use as a therapeutically active substance in treatment of neoplastic proliferative diseases with an impaired mechanism of apoptosis.
The use of the maltotriose-coated 4th generation polypropyieneimine dendrimer—PPI-G4-OS-Mal-III of Pattern 1, wherein R stands for a maltotriose residue and the number of surface maltotriose groups (Mal-III) forming the open coat (OS) ranges from 22 to 32 and corresponds to 35% to 50%, based on a number of amino groups of the 4th generation polypropyleneimine dendrimer (PPI-G4) particle, as a anti-neoplastic agent, for manufacturing a composition for treatment or alleviation of the neoplastic proliferative disease, with an impaired mechanism of apoptosis in humans, comprising said PPI-G4-OS-Mal-III dendrimer in an effective amount, providing achieving the desired therapeutic result.
A pharmaceutical composition for treatment or alleviation of the neoplastic proliferative disease, with an impaired mechanism of apoptosis in humans, wherein said composition is in form suitable for i.v. administration and comprises said PPI-G4-OS-Mal-III dendrimer in an effective amount, when applied once a day or more than once a day, in combination with suitable vehicle, adjuvants and optionally other biologically active substances.
Dependencies are inferred from the claim text.